Annals of Surgical Oncology

, Volume 22, Issue 11, pp 3512–3521 | Cite as

FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma

  • Eran Sadot
  • Alexandre Doussot
  • Eileen M. O’Reilly
  • Maeve A. Lowery
  • Karyn A. Goodman
  • Richard Kinh Gian Do
  • Laura H. Tang
  • Mithat Gönen
  • Michael I. D’Angelica
  • Ronald P. DeMatteo
  • T. Peter Kingham
  • William R. Jarnagin
  • Peter J. AllenEmail author
Pancreatic Tumors



Reports show that FOLFIRINOX therapy for pancreatic ductal adenocarcinoma (PDAC) results in objective response rates two to threefold higher than those of other regimens. This study aimed to assess response and resection rates for locally unresectable (stage 3) patients initially treated with induction FOLFIRINOX.


The institutional cancer database was queried for patients treated with induction FOLFIRINOX therapy between 2010 and 2013. Patients were included in the study if they were treated at the authors’ institution for stage 3 PDAC (locally unresectable) that had been adjudicated at a weekly multidisciplinary tumor board.


The study identified 101 patients. The median age was 64 years (range 37–81 years), and the median follow-up period was 12 months (range 3–37 months). The patients received a median of six cycles (range 1–20 cycles) of induction FOLFIRINOX. No grade 4 or 5 toxicity was recorded. At the initial restaging (median of 3 months after diagnosis), 23 patients (23 %) had developed distant metastases, 15 patients (15 %) had undergone resection, and 63 patients (63 %) had proceeded to chemoradiation. In the group of 63 patients who had proceeded to chemoradiation (median of 9 months after diagnosis), an additional 16 patients (16 %) had undergone resection, and 5 patients (5 %) had developed metastases. A partial radiographic response was observed in 29 % of all the patients, which was associated with ability to perform resection (p = 0.004). The median overall survival time was 11 months for the group that progressed with FOLFIRINOX and 26 months for the group that did not progress.


Nearly one third of the patients who had been initially identified as having stage 3 pancreatic carcinoma and had been treated with FOLFIRINOX responded radiographically and underwent tumor resection.


Gemcitabine Induction Therapy Objective Response Rate Pancreatic Ductal Adenocarcinoma Resectable Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



This study was funded in part by NIH/NCI Cancer Center Support Grant P30 CA008748.


There are no conflicts of interest.

Supplementary material

10434_2015_4647_MOESM1_ESM.doc (140 kb)
Supplementary material 1 (DOC 139 kb)


  1. 1.
    Conroy T, Desseigne F, Ychou M, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.CrossRefPubMedGoogle Scholar
  2. 2.
    Marthey L, Sa-Cunha A, Blanc JF, et al. (2014) FOLFIRINOX for locally advanced pancreatic adenocarcinoma: results of an AGEO multicenter prospective observational cohort. Ann Surg Oncol. doi: 10.1245/s10434-014-3898-9.PubMedGoogle Scholar
  3. 3.
    Faris JE, Blaszkowsky LS, McDermott S, et al. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience. Oncologist. 2013;18:543–8.PubMedCentralCrossRefPubMedGoogle Scholar
  4. 4.
    O’Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260:142–8.PubMedCentralCrossRefPubMedGoogle Scholar
  5. 5.
    Bickenbach KA, Gonen M, Tang LH, et al. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Ann Surg Oncol. 2012;19:1663–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Ammori JB, Colletti LM, Zalupski MM, et al. Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg. 2003;7:766–72.CrossRefPubMedGoogle Scholar
  7. 7.
    Cardenes HR, Moore AM, Johnson CS, et al. A phase II study of gemcitabine in combination with radiation therapy in patients with localized, unresectable, pancreatic cancer: a Hoosier Oncology Group study. Am J Clin Oncol. 2011;34:460–5.CrossRefPubMedGoogle Scholar
  8. 8.
    Massucco P, Capussotti L, Magnino A, et al. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol. 2006;13:1201–8.CrossRefPubMedGoogle Scholar
  9. 9.
    Small W Jr., Berlin J, Freedman GM, et al. Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol. 2008;26:942–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Aristu J, Canon R, Pardo F, et al. Surgical resection after preoperative chemoradiotherapy benefits selected patients with unresectable pancreatic cancer. Am J Clin Oncol. 2003;26:30–6.CrossRefPubMedGoogle Scholar
  11. 11.
    Leone F, Gatti M, Massucco P, et al. Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer. 2013;119:277–84.CrossRefPubMedGoogle Scholar
  12. 12.
    Bajetta E, Di Bartolomeo M, Stani SC, et al. Chemoradiotherapy as preoperative treatment in locally advanced unresectable pancreatic cancer patients: results of a feasibility study. Int J Radiat Oncol Biol Phys. 1999;45:285–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Kim HJ, Czischke K, Brennan MF, Conlon KC. Does neoadjuvant chemoradiation downstage locally advanced pancreatic cancer? J Gastrointest Surg. 2002;6:763–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Ferrone CR, Marchegiani G, Hong TS, et al. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261:12–7.CrossRefPubMedGoogle Scholar
  15. 15.
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology, Version 1.2014. Accessed 10 Feb 2014.
  16. 16.
    Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.CrossRefPubMedGoogle Scholar
  17. 17.
    National Cancer Institute. Cancer Therapy Evaluation Program. Common Toxicity Criteria Manual, Version 4.0. Accessed 20 Feb 2014.
  18. 18.
    Grobmyer SR, Pieracci FM, Allen PJ, Brennan MF, Jaques DP. Defining morbidity after pancreaticoduodenectomy: use of a prospective complication grading system. J Am Coll Surg. 2007;204:356–64.CrossRefPubMedGoogle Scholar
  19. 19.
    DeOliveira ML, Winter JM, Schafer M, et al. Assessment of complications after pancreatic surgery: a novel grading system applied to 633 patients undergoing pancreaticoduodenectomy. Ann Surg. 2006;244:931–7; discussion 937–9.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Katz MH, Fleming JB, Bhosale P, et al. Response of borderline resectable pancreatic cancer to neoadjuvant therapy is not reflected by radiographic indicators. Cancer. 2012;118:5749–56.CrossRefPubMedGoogle Scholar
  21. 21.
    Von Hoff DD, Ervin T, Arena FP, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691–703.CrossRefGoogle Scholar
  22. 22.
    Boone BA, Steve J, Krasinskas AM, et al. Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer. J Surg Oncol. 2013;108:236–41.CrossRefPubMedGoogle Scholar
  23. 23.
    Hosein PJ, Macintyre J, Kawamura C, et al. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma. BMC Cancer. 2012;12:199.PubMedCentralCrossRefPubMedGoogle Scholar

Copyright information

© Society of Surgical Oncology 2015

Authors and Affiliations

  • Eran Sadot
    • 1
  • Alexandre Doussot
    • 1
  • Eileen M. O’Reilly
    • 2
  • Maeve A. Lowery
    • 2
  • Karyn A. Goodman
    • 3
  • Richard Kinh Gian Do
    • 4
  • Laura H. Tang
    • 5
  • Mithat Gönen
    • 6
  • Michael I. D’Angelica
    • 1
  • Ronald P. DeMatteo
    • 1
  • T. Peter Kingham
    • 1
  • William R. Jarnagin
    • 1
  • Peter J. Allen
    • 1
    Email author
  1. 1.Department of SurgeryMemorial Sloan Kettering Cancer CenterNew YorkUSA
  2. 2.Department of MedicineMemorial Sloan Kettering Cancer CenterNew YorkUSA
  3. 3.Department of Radiation OncologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  4. 4.Department of RadiologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  5. 5.Department of PathologyMemorial Sloan Kettering Cancer CenterNew YorkUSA
  6. 6.Department of Epidemiology and BiostatisticsMemorial Sloan Kettering Cancer CenterNew YorkUSA

Personalised recommendations